Candida auris fungemia confirmed by Sanger sequencing method: A rare case report

Yıl 2025, Cilt: 35 Sayı: 4, 782 - 787, 29.08.2025

Burak Ezer , Hilal Sena Çiftci , Selin Uğraklı , Rukiyye Bulut , Funda Gök

https://doi.org/10.54005/geneltip.1574493

Öz

ABSTRACT
Candida auris infections are an important fungal pathogen that have been on the rise worldwide in recent years and have become a serious problem in intensive care units. In our patient with a long history of intensive care unit hospitalization, diabetes mellitus as a comorbidity, and a history of broad-spectrum antibiotic use; C.auris was isolated from blood cultures by both MALDI-TOF MS and Sanger sequencing method. Antifungal susceptibility was determined by liquid microdilution method and intravenous caspofungin treatment was first given to the patient and intravenous liposomal amphotericin B treatment was initiated when C.auris was grown again in the blood cultures. Although C.auris eradication was achieved on the 77th day of antifungal treatment and 27th day of amphotericin B treatment, the patient died with septic shock due to panresistant Providencia stuartii infection. Our case is the first reported case from Konya and clinicians should be cautious against C. auris cases with multidrug resistance which may lead to outbreaks in intensive care units.

Anahtar Kelimeler

Resistant , Candida auris , Fungemia

Etik Beyan

Signed informed consent was obtained from the patient's daughter.

Destekleyen Kurum

-

Teşekkür

-

Kaynakça

• 1. Ahmad S, Alfouzan W. Candida auris: Epidemiology, diagnosis, pathogenesis, antifungal susceptibility, and infection control measures to combat the spread of infections in healthcare facilities. Microorganisms 2021;9(4):807.
• 2. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 2009; 53(1): 41-4.
• 3. Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69.
• 4. Irinyi L, Serena C, Garcia-Hermoso D, Arabatzis M, Olivier MD, Vu D, et al. International Society of Human and Animal Mycology (ISHAM)- ITS reference DNA barcoding database - The quality-controlled standard tool for routine identification of human and animal pathogenic fungi. Med Mycol 2015;53(4):313-37.
• 5. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis. Primers 2018; 4(1): 1-20.
• 6. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A, et al. Candida auris: A Review of the Literature. Clin Microbiol Rev. 2017;31(1):e00029-17.
• 7. Kurt AF, Kuskucu MA, Balkan II, Barıs A, Yazgan Z, Oz AZ, et al. Candida auris Fungemia and a local spread taken under control with infection control measures: First report from Turkey. Indian J Med Microbiol 2021;39(2):228-30. https://doi.org/10.1016/j.ijmmb.2021.03.007.
• 8. Kömeç S, Karabıçak N, Ceylan AN, Gülmez A, Özalp O. Türkiye İstanbul’dan bildirilen üç Candida auris olgusu. Mikrobiyol Bul 2021;55(3):452-60.
• 9. Teke L, Sargin Altunok E, Genç Moralar D. The second case of Candida auris candidemia from Turkey: An impending threat to global health. Mediterr J Infect Microbes Antimicrob 2021;10:48. https://doi.org/10.4274/mjima.galenos.2021.2021.48.
• 10. Kulaklı K, Arslan N, Gürsan O, Özkütük A. İzmir’den ilk Candida auris izolasyonu: Amputasyon ile sonuçlanan polimikrobiyal diyabetik ayak enfeksiyonu. Turk Mikrobiyol Cemiy Derg 2023;53(1):47-54.
• 11. Centers for Disease Control and Prevention. Infection prevention and control for Candida auris. 23 April 2024. Available at: https://www.cdc.gov/candida-auris/hcp/laboratories/antifungal-susceptibility-testing.html.
• 12. Kim M-N, Shin JH, Sung H, Lee K, Kim E-C, Ryoo N, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis 2009; 48(6): e57-e61.
• 13. Oh BJ, Shin JH, Kim M-N, Sung H, Lee K, Joo MY, et al. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Med Mycol 2011; 49(1): 98-102.
• 14. Hu S, Zhu F, Jiang W, Wang Y, Quan Y, Zhang G, et al. Retrospective analysis of the clinical characteristics of Candida auris infection worldwide from 2009 to 2020. Front Microbiol 2021;12:658329.
• 15. Pandya N, Cag Y, Pandak N, Pekok AU, Poojary A, Ayoade F, et al. International multicentre study of Candida auris infections. J Fungi 2021;7(10):878. https://doi.org/10.3390/jof7100878.
• 16. Alp Ş. Candida auris and Mechanisms of Antifungal Drug Resistance. Mikrobiyol Bul 2021; 55(1): 99-112.
• 17. Ostrowsky B, Greenko J, Adams E, Quinn M, O’ Brien B, Chaturvedi V, et al. Candida auris isolates resistant to three classes of antifungal medications - New York, 2019. MMWR Morb Mortal Wkly Rep 2020;69(1):6-9. https://doi.org/10.15585/mmwr.mm6901a2.
• 18. Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 2017; 13(5): e1006290.
• 19. Eyre DW, Sheppard AE, Madder H, Moir I, Moroney R, Quan TP, et al. A Candida auris outbreak and its control in an intensive care setting. N Eng J Med 2018; 379(14): 1322-31.
• 20. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol 2011; 49(9): 3139-42.